H Lundbeck A/S (OTCPK:HLUYY)
(LUN.CO) remains in a "hurry up and wait" gray area. Key drugs like
Brintellix and Abilify Maintena are only just getting started and
investors are on tenterhooks waiting for Phase III data on key pipeline
candidates like brexpiprazole and desmoteplase. While the shares still
look undervalued today, further progression in the Brintellix launch and
key pipeline updates will likely lead to significant revisions in
estimated value before 2014 is over.
Read more here:
Lundbeck Starting Slow, But Still Looking For The Big Finish
No comments:
Post a Comment